MedTrace Logo

Clinical Study Evaluating Targeted Biopsies and Cytological Imprints in Prostate Cancer

NCT01745718 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-09-23

No results posted yet for this study

Summary

The investigators will evaluate the accuracy of performing cytological imprints of targeted biopsies when diagnosing prostate cancer.

It is useful to know whether the biopsy is cancer or not, in order to know when to stop sampling and when to continue.

The strategy is used in other types of cancer, e.g lung, breast etc

Conditions

Interventions

OTHER

Cytological imprints

Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Eduard Baco, MD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-08-31
Completion
2013-09-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01745718 on ClinicalTrials.gov